Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape

Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape
Preview
Source: Business Wire
'Since the pandemic we have seen a rapid increase in transitioning legacy systems to strategic digital solutions, especially in the life sciences vertical'
Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape
Preview
Source: Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--SoftServe, a leader in digital services and consulting, has been recognized as an Aspirant in Everest Group's Life Sciences Digital Services PEAK Matrix® Assessment 2022. Everest Group is a provider of strategic research insights on IT, business processes, and engineering services and a global Business Process Outsourcing (BPO) research firm.
The Life Sciences Digital Services PEAK Matrix® Assessment 2022 covers the top digital life sciences service providers, best-in-class solutions and products, and top locations, according to Everest Group's research. This is the first time SoftServe has been named in the Life Sciences sector.
SoftServe debuted with an impressive score in Everest Group's two assessment areas: vision and strategy along with value delivered. Everest Group recognized SoftServe’s expertise in a consulting-led approach to deliver AI and analytics-based domain-specific digital platforms and custom solutions with accelerators, including Human360°, data management, and omnichannel engagement. SoftServe was also recognized for strategic initiatives in talent upskilling through investments in SoftServe University, data and analytics CoE, and professional certifications.
“Since the pandemic we have seen a rapid increase in transitioning legacy systems to strategic digital solutions, especially in the life sciences vertical,” said Steve LoSardo, vice president of Life Science Domain Solutions and Consulting, SoftServe. “Clients are seeking innovative partners to guide them in making the right decisions, create solutions to solve specific business issues and build effective long-term digital strategies and that is exactly how SoftServe operates. This assessment displays our deep expertise across biopharmaceutical and medical device enterprises, and our reputation for delivering excellence through quality talent and products.”
Everest Group specifically called out biopharmaceutical and medical devices enterprise clients and acknowledged SoftServe’s delivery excellence and quality of talent as key strengths. Download the full report.
SoftServe has also been recognized as a Major Contender in the Healthcare Analytics Services PEAK Matrix® Assessment, the Healthcare Payer Digital Services PEAK Matrix® Assessment, and the Digital Product Engineering Services PEAK Matrix® Assessment.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize how enterprises and software companies do business. Our end-to-end solutions and expertise deliver innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s marketplace—no matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.